E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Great Debates and Updates in Breast Cancer


Register Now

Great Debates and Updates in Breast Cancer

May 7 - 8, 2010

San Francisco, California

 

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 9.75 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Who Should Attend

This educational activity is specifically designed for medical oncologists, radiation oncologists, breast cancer specialists, surgical oncologists, pathologists and other allied healthcare professionals involved in the management of breast cancer.

 

Objectives

After successful completion of this educational activity, attendees should be able to:

  • Determine how novel strategies in the surgical management of breast cancer and new recommendations for post-surgery therapy can improve patient outcomes
  • Evaluate whether intense surveillance techniques should be conducted to adequately assess recurrence of risk and individualization of breast cancer therapy
  • Identify the new predictive factors for determining intrinsic resistance for various therapeutic strategies in breast cancer
  • Comment on emerging research in genetic profiling and biomarkers for breast cancer that can influence choice of therapy
  • Interpret and integrate recent clinical trial data on emerging agents for the prevention and treatment of localized and metastatic breast cancer including anti-HER2 agents, anti-tubulin agents, and bisphosphonates
  • Summarize optimal hormonal therapy for ER+ stage breast cancer
  • Adequately address controversial questions in the optimal use of anti-HER2 agents, including recommendations for early stage HER2+ breast cancer, therapeutic strategies following disease progression, and approaches to combat anti-HER2 resistance
    ategies in the surgical management of breast cancer and new recommendations for post-surgery therapy can improve patient outcomes

Benjamin O. Anderson, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington

 

Scott D. Christensen, MD
University of California, Davis Cancer Center
Sacramento, California

 

Barbara L. Fowble, MD,
FACR, FASTRO
UCSF Comprehensive Cancer Center
San Francisco, California

 

William J. Gradishar, MD, FACP
Northwestern University
Chicago, Illinois


Mohammad Jahanzeb,
MD FACP
Lynn Cancer Institute – West Campus
Boca Raton, Florida

 

Virginia Kaklamani, MD, DSc
Northwestern University
Chicago, Illinois

 

Minetta C. Liu, MD
Lombardi Comprehensive
Cancer Center and
Georgetown University Hospital
Washington, DC

 

Pamela N. Munster, MD
University of California,
San Francisco
San Francisco, California

 

Hope Rugo, MD
University of California, San Francisco
San Francisco, California

 

Lawrence J. Solin, MD
Albert Einstein Medical Center
Philadelphia, Pennsylvania

 

Deborah L. Toppmeyer, MD
The Cancer Institute of
New Jersey
New Brunswick, New Jersey

 

Denise A. Yardley, MD
Sarah Cannon Research Institute
Nashville, Tennessee

Friday, May 7, 2010

9:00 am
Welcome and introduction
William J. Gradishar, MD, FACP
and Hope Rugo, MD

9:10 am
Pre-session audience survey

9:20 am
Debate: Should all patients undergo MRI screening prior to surgery? Are all MRI
scans the same?
Yes: Speaker invited
No: Lawrence Solin, MD

9:50 am
Debate: Should trastuzumab be recommended for all women with stage I HER2+ breast cancer?
Yes: Pamela N. Munster, MD
No: William Gradishar, MD

10:20 am
Didactic: Is gene expression profiling useful in treatment planning for node positive breast cancer?
Deborah Toppmeyer, MD

10:40 am
Questions and discussion

10:50 am
Coffee break

11:10 am
Didactic: Emerging therapies for targeting HER2-positive breast cancer: current and future directions
Hope Rugo, MD

11:30 am
Debate: Is continuing trastuzumab in combination with chemotherapy the best treatment strategy following disease progression on trastuzumab?
Yes: Scott D. Christensen, MD
No: Virginia Kaklamani, MD

12:00 pm
Questions and discussion

12:10 pm
Lunch break

1:10 pm
Debate: Should additional chemotherapy therapy be given for residual disease at the time of surgery following anthracycline and taxane based neoadjuvant chemotherapy?
Yes: Mohammad Jahanzeb, MD
No: Pamela N. Munster, MD

1:40 pm
Debate: Should we recommend post mastectomy radiation to all patients with node positive breast cancer?
Yes: Lawrence Solin, MD
No: Barbara Fowble, MD

2:10 pm
Didactic: BRCA status: impact on therapeutic decision-making
Virginia Kaklamani, MD

2:20 pm
Questions and discussion

2:40 pm
Coffee break

3:00 pm
Debate: Can anthracyclines be eliminated as a component of chemotherapy in patients with early stage breast cancer?
Yes, 4 cycles of TC is an appropriate substitute: Denise Yardley, MD
No, anthracyclines are here to stay: Mohammad Jahanzeb, MD

3:30 pm
Didactic: Role of new and emerging chemotherapy agents targeting the microtubule in the treatment of advanced breast cancer.
Denise A. Yardley, MD

4:00 pm
Questions and discussion

4:10 pm
Adjourn

Saturday, May 8, 2010

8:30 am
Introduction
William J. Gradishar, MD, FACP
and Hope Rugo, MD

8:35 am
Pre-session audience survey

8:45 am
Didactic: Optimal hormonal therapy and symptom management for ER-positive menopausal early stage breast cancer
Deborah L. Toppmeyer, MD

9:05 am
Debate: Should bevacizumab be continued beyond disease progression?
Yes: Hope Rugo, MD
No: Scott D. Christensen, MD

9:35 am
Debate: Should ovarian suppression be routinely prescribed for premenopausal women with high risk early stage breast cancer?
Yes: William J. Gradishar, MD, FACP
No: Terry Mamounas, MD

10:05 am
Questions and discussion

10:15 am
Coffee break

10:35 am
Didactic: Evolving use of oncoplastic surgery in the management of breast cancer
Benjamin Anderson, MD

10:55 am
Debate: Should all patients with de novo stage IV disease have primary breast cancer surgery?
Yes: Benjamin Anderson, MD
No: Terry Mamounas, MD

11:25 am
Questions and discussion

11:35 am
Lunch break

12:35 pm
Debate: Bisphosphonates should be routinely used to prevent disease recurrence in women with early stage breast cancer
Yes: Speaker invited
No: Minetta C. Liu, MD

1:05 pm
Didactic: Evolving use of circulating tumor cells and tumor markers in the management of metastatic breast cancer.
Minetta C. Liu, MD

1:25 pm
Questions and discussion

1:40 pm
Post-meeting audience survey

2:00 pm
Adjourn

Registration Fees

Regular..................................................... $150
If payment received by April 29, 2010

Full/Onsite.................................................$250
If payment received after April 29, 2010

Nurses/Residents/Students*........................$75
*proof of eligibility must accompany registration
*cannot be combined with any other discounts

 

To Register

You may register online by April 29, 2010 at www.imedex.com or by calling Imedex at +1 678.242.0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

 

Payment

To pre-register, registration and payment must be received no later than April 29, 2010. Please register onsite after this date. Contact Imedex at +1 678.242.0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

 

Registration Fee Inclusions

Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

 

Cancellation

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 29, 2010. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 29, 2010.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.


Hilton San Francisco Financial District
750 Kearny Street
San Francisco, CA 94108
T: +1 415.433.6600
F: +1 415.765.7891
W: www.sanfranciscohiltonhotel.com

 

Soaring 27 stories over the "City by the Bay", the Hilton San Francisco Financial District hotel offers stunning panoramic views and the perfect location for business or leisure travel. Located in the historic center of the city, the hotel sits at the crossroads of the Financial District, Chinatown, North Beach and Nob Hill. Within bustling, culturally diverse surrounding neighborhoods you are just steps away from San Francisco's most popular attractions such as Alcatraz, Coit Tower, Lombard Street and the Golden Gate Bridge. For premium San Francisco shopping, catch a ride on San Francisco's historic Cable Cars to several locations including Union Square, Embarcadero Center, Westfield Mall, Fisherman's Wharf, Ghirardelli Square and the Ferry Building.

For the convenience of attendees, a limited number of rooms have been reserved until April 15, 2010 at a discounted rate of $139 single/double occupancy, plus tax, currently at 14.07% and the San Francisco TID assessment of 1.5%. A $25 per person charge will apply for the third or fourth person per guest room. This rate is not guaranteed outside the conference dates or after April 15, 2010.

To reserve your room please contact the Hilton Financial District reservations department at +1 415.433.6600 or visit the hotel’s website at http://www.hilton.com/en/hi/groups/personalized/SFOFDHF-IME-20100503/index.jhtml?WT.mc_id=POG. To receive the group rate, callers must identify themselves as being with the Great Debates in Breast Cancer group. Reservation requests received after April 15, 2010 may not be guaranteed the group rate.

 

Conference Location and Registration

Hilton San Francisco Financial District
750 Kearny Street
San Francisco, CA 94108
T: +1 415.433.6600
F: +1 415.765.7891
W: www.sanfranciscohiltonhotel.com

 

The Registration and Information Desk
will be staffed:

Friday, May 7, 2010
7:30 am – 4:00 pm

Saturday, May 8, 2010
8:00 am – 2:00 pm

 

Important Dates

Regular Registration Deadline
April 29, 2010

Presentation Dates
May 7 – 8, 2010

 

pdf download

 

Chairs

William J. Gradishar, MD, FACP
Northwestern University
Chicago, California

Hope Rugo, MD
University of California, San Francisco
San Francisco, California


Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
T: +1 770.751.7332
F:: +1 770.751.7334
E: meetings@imedex.com
W: www.imedex.com


 

The following companies have provided an educational grant in support of this conference:

Silver:

Genentech BioOncology

 

Bronze:

BMS

 

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1770.751.7332, or by email at cme@imedex.com.

 

 

The following companies are exhibitors at this conference:

Agendia

Eisai

Monogram Bioscience

 

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1 678.242.0712, or by email at c.gunter@imedex.com.